- CagriSema combines cagrilintide and semaglutide for weight loss.
- 68-week REDEFINE 1 trial included 3,417 participants.
- Mean weight loss of 20.4% in CagriSema group.
- 91.9% lost at least 5% of body weight.
- Significant metabolic improvements noted.
- Common side effects included gastrointestinal issues.
- A follow-up study is assessing CagriSema in type 2 diabetes.
Once-Weekly Combo Injection Cuts Weight by 20%
Conexiant
July 9, 2025